Activated Cancer Therapy Using Light and Ultrasound - A Case Series of Sonodynamic Photodynamic Therapy in 115 Patients over a 4 Year Period

Activated Ca ncer Ther apy ( ACT), al so know n a s Sonodyna mic Phot odynamic Ther apy ( SPDT) i s a nove l therapeutic modality that utilises a non-toxic photosensitive agent with reported ultrasound-activated properties. SPDT has previously demonstrated significant tumour cell inhibition in animal studies. There has been much research into the effi- cacy of phot odynamic therapy and development in understanding of the underlying mechanism of tumour cytotoxicity. Synergistic ultrasound activation represents a promising development to activated sensitiser therapy, as photo-activation is limited by access and penetrance issues. Ultrasound has been demonstrated to activate a number of sono-sensitive agents allowing the possibility of non-invasive targeted treatment o f deeper tumour sites than is currently achievable with pho- todynamic therapy. Thi s case se ries of 115 pa tients w ith a v ariety of ca ncer di agnoses reports on experiences of this treatment over a 4 year period using sublingual administration of a new dual activation agent, Sonnelux-1, followed by a protocol of LED light and low-intensity ultrasound exposure. Initial clinical observation suggests SPDT is worthy of fur- ther investigation a s an ef fective and w ell to lerated t reatment fo r a w ide v ariety o f p rimary an d m etastatic tumours, in- cluding those refractory to chemotherapy. Key Wo rds: Sonodynamic therapy, photodynamic therapy, activated cancer therapy, u ltrasound activated therapy, m etastatic cancer, sonnelux-1, dove clinic, sonnemed.